|Chemical and physical data|
|Molar mass||225.284 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Prenalterol exhibits adrenergic agonist activity in spite of an interposed oxymethylene group. The stereospecific synthesis devised for this molecule relies on the fact that the side chain is very similar in oxidation state to that of a sugar.
Condensation of monobenzone (2) with the epoxide derived from α-D-glucofuranose affords the glycosylated derivative (3). Hydrolytic removal of the acetonide protecting groups followed by cleavage of the sugar with periodate gives aldehyde (4). This is reduced to the glycol by means of NaBH4 and the terminal alcohol is converted to the mesylate (5). Displacement of the leaving group with isopropylamine followed by hydrogenolytic removal of the O-benzyl ether affords the β1-adrenergic selective adrenergic agonist prenalterol (6).
Prepns of the racemic mixture: NL 6409883 corresp to H. Köppe et al., U.S. Patent 3,637,852 (1965, 1972 both to Boehringer Ingelheim); NL 301580 corresp to A. F. Crowther, L. H. Smith, U.S. Patent 3,501,769 (1965, 1970 both to ICI);
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|